These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9458447)

  • 1. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
    Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
    Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
    Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
    Andersen K; Dellborg M; Emanuelsson H; Grip L; Swedberg K
    Coron Artery Dis; 1996 Sep; 7(9):673-81. PubMed ID: 8950498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
    Andersen K; Dellborg M
    Am J Cardiol; 1998 Apr; 81(8):939-44. PubMed ID: 9576150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
    Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
    Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
    Direct Thrombin Inhibitor Trialists' Collaborative Group
    Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
    N Engl J Med; 1996 Sep; 335(11):775-82. PubMed ID: 8778585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation activity and clinical outcome in unstable coronary artery disease.
    Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):1059-64. PubMed ID: 11397720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
    Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
    J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
    Cohen M; Xiong J; Parry G; Adams PC; Chamberlain D; Wieczorek I; Fox KA; McBride R; Chesebro JH; Fuster V
    J Am Coll Cardiol; 1993 Nov; 22(5):1338-43. PubMed ID: 7901254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
    Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
    Uriuda Y; Wang QD; Grip L; Rydén L; Sjöquist PO; Mattsson C
    Cardiovasc Res; 1996 Aug; 32(2):320-7. PubMed ID: 8796119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
    Chen L; Nichols WW; Mattsson C; Teger-Nilsson AC; Saldeen TG; Mehta JL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1276-83. PubMed ID: 8667188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.